Cargando…

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

SIMPLE SUMMARY: The acceptable safety profile of immunotherapy may affect the risk-benefit ratio analysis of treatment prescription near the late stage of life for advanced non-small cell lung cancer patients. The aim of our retrospective study was to describe the clinical characteristics of patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Giglio, Andrea, Tassinari, Elisa, Zappi, Arianna, Di Federico, Alessandro, Lenzi, Barbara, Sperandi, Francesca, Melotti, Barbara, Gelsomino, Francesco, Maltoni, Marco, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739118/ https://www.ncbi.nlm.nih.gov/pubmed/36497326 http://dx.doi.org/10.3390/cancers14235845

Ejemplares similares

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
por: Comito, Francesca, et al.
Publicado: (2022)

Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients
por: Scarpi, Emanuela, et al.
Publicado: (2022)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Prognostication in palliative radiotherapy—ProPaRT: Accuracy of prognostic scores
por: Maltoni, Marco, et al.
Publicado: (2022)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

Genomic and Proteomic Analyses of the Terminally Redundant Genome of the Pseudomonas aeruginosa Phage PaP1: Establishment of Genus PaP1-Like Phages
por: Lu, Shuguang, et al.
Publicado: (2013)

BRAF‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
por: Abbati, Francesca, et al.
Publicado: (2021)

Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
por: De Giglio, Andrea, et al.
Publicado: (2022)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
por: Dall’Olio, Filippo G., et al.
Publicado: (2022)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Global Transcriptomic Analysis of Interactions between Pseudomonas aeruginosa and Bacteriophage PaP3
por: Zhao, Xia, et al.
Publicado: (2016)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Unlocking the mystery of the hard-to-sequence phage genome: PaP1 methylome and bacterial immunity
por: Lu, Shuguang, et al.
Publicado: (2014)

Functional identification of the DNA packaging terminase from Pseudomonas aeruginosa phage PaP3
por: Shen, Xiaodong, et al.
Publicado: (2012)

P1674: PAP SCORE (PALLIATIVE PROGNOSTIC SCORE) ESTIMATES SHORT-TERM SURVIVAL IN A COHORT OF HEMATOLOGICAL PATIENTS
por: Facchinelli, Davide, et al.
Publicado: (2023)

Who needs and continues to need paediatric palliative care? An evaluation of utility and feasibility of the Paediatric Palliative Screening scale (PaPaS)
por: Chong, Poh Heng, et al.
Publicado: (2020)

Adaptation of Pseudomonas aeruginosa to Phage PaP1 Predation via O-Antigen Polymerase Mutation
por: Li, Gang, et al.
Publicado: (2018)

Transcriptomic and Metabolomics Profiling of Phage–Host Interactions between Phage PaP1 and Pseudomonas aeruginosa
por: Zhao, Xia, et al.
Publicado: (2017)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

PaP1, a Broad-Spectrum Lysin-Derived Cationic Peptide to Treat Polymicrobial Skin Infections
por: Heselpoth, Ryan D., et al.
Publicado: (2022)

The development of an instrument that can identify children with palliative care needs: the Paediatric Palliative Screening Scale (PaPaS Scale): a qualitative study approach
por: Bergstraesser, Eva, et al.
Publicado: (2013)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Poly(A) polymerase (PAP) diversity in gene expression – Star-PAP vs canonical PAP
por: Laishram, Rakesh S.
Publicado: (2014)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
por: Ricci, Costantino, et al.
Publicado: (2020)

Collaborative Care in NSCLC; the Role of Early Palliative Care
por: Howe, Marnie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_iv9ngfg3p45joag7oqijq8esk0